HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 06, June 2018 – Cancer - Therapies and strategies for better patient outcomes       » Gardasil 9 supply running short in Hong Kong       » China helps Tajikistan tackle grassland degradation       » Immuno-oncology trials in China surge more than 50 per cent       » Yeast for industrial biotechnology       » Uncontrolled hypertension in rural communities      
INSIDE INDUSTRY
3D cell culture firm Reinnervate and specialist Oncology CRO Oncotest GmbH enter collaboration agreement
Reinnervate Ltd, announced that it has entered into a co-marketing agreement with the pre-clinical Oncology CRO Oncotest GmbH.

Under the terms of the partnership, Oncotest will offer its clients automated assays based on Alvetex ®Scaffold technology, complementing their well-known 3D Tumour Clonogenic Assay technology.

Prof. Stefan Przyborski, founder and CSO of Reinnervate described the benefits of the 96 well plates for cancer cell cytotoxicity testing; The Alvetex ®Scaffold 96 well plate allows scientists to grow tumour cells in 3D, better mimicking the way these cells grow in vivo. It is very easy to start using 3D cell culture with Alvetex ® technology. You simply seed the cells, add your existing media and place in your standard incubator. There is no struggling with new and sometimes cumbersome protocols required with other 3D technologies such as collagen gels or hanging drops. He then went on to say; We have shown that the Alvetex ®Scaffold 96 well plates work seamlessly with automated platforms and standard cell health assays such as MTT, XTT, Cell Titer-Glo ® and many others.

Prof. Heiner Fiebig, founder and CEO of Oncotest said, We are very pleased to be able to offer cancer cell cytotoxicity assays using Alvetex ®Scaffold 96 well plates to our clients. We have looked at several different technologies and found Alvetex ®Scaffold to be the simplest and most reliable solution. We particularly value the ease of use, ability to automate the entire workflow and the ability to isolate protein and RNA from the treated cells to study drug effects post-treatment. The combination of Alvetex ®Scaffold, state-of-the-art co-culture techniques and our automated 96 well 3D assay technology will also potentially allow the study of effects of anti-cancer molecules which target parts of the tumour microenvironment. This powerful ex vivo culture system will be a very exciting new tool for our clients. The assay platform can be used with both Oncotest's patient-derived tumour xenografts (as an ex vivo assay) and for established tumour cell lines (as an in vitro assay).

Oncotest will begin offering services immediately to existing clients, and will offer a new introductory screening service for companies new to 3D cell culture who want to try out 3D culture based oncology services.

Click here for the complete issue.

NEWS CRUNCH  
news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
Click here to receive APBN e-newsletters once a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Cancer - Therapies and strategies for better patient outcomes
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy